Duke-NUS unveils LIVE Ventures to catalyze the commercialization of academic research

FHS
July 22, 2024
10:49 am

Duke-NUS Medical School today launched LIVE Ventures, a S$20 million incubation programme designed to catalyse the commercialisation of innovative academic research.

Early Improvement in Prurigo Nodularis With IL-31 Antagonist Maintained at 1 Year

SAN DIEGO — More than two-thirds of patients with prurigo nodularis obtained long-term relief from itching, skin lesions, and sleep disturbance with the interleukin (IL)-31

March 13, 2024

New study opens unprecedented opportunities for bioengineering vaccine adjuvants

A valuable molecule sourced from the soapbark tree and used as a key ingredient in vaccines, has been replicated in an alternative plant host for

January 27, 2024

Psychedelic Research Bulletin: December 2023 – Psychedelic Alpha

A Phase II trial affirmed the safety and efficacy of psilocybin-assisted therapy in a group setting, with a majority experiencing sustained response and remission from

January 4, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.